PAC‐14028 cream for atopic dermatitis. (1st May 2019)

• Record Type: Journal Article
• Authors: Lee, Y.W.; Won, C.‐H.; Jung, K.; Nam, H.‐J.; Choi, G.; Park, Y.‐H.; Park, M.; Kim, B.
• Is Part Of: British journal of dermatology. Volume 180:Number 5(2019)
• Page Start: e163
• Page End: e163
• Publication Date: 2019-05-01
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.17802
• Languages: English
• ISSNs: 0007-0963

Abstract

Summary: This research, from Korea, showed that a non‐steroid containing cream, called PAC‐14028, can be as effective in treating eczema symptoms as current creams on the market but with fewer side‐effects. Eczema is one of the most common skin diseases. Available topical (applied to the skin) treatments can be very effective in treating eczema symptoms. However, they can also cause negative side‐effects such as itching and burning, which can result in patients discontinuing their treatment. The research was conducted with 194 adults with mild to moderate eczema. Participants were split into four groups and treated with either a control cream or the new treatment, PAC‐14028 cream, at one of three different concentrations (0.1%, 0.3% or 1.0%). Participants applied the cream twice daily for eight weeks. The results were primarily measured using the Investigator's Global Assessment (IGA). This is a visual scale for assessing the severity of eczema in a patient based upon typical symptoms. After eight weeks, 57.5 percent of patients in the group who received the highest concentration PAC‐14028 cream, had an IGA score indicating that their symptoms of eczema were completely eradicated or reduced to an almost‐clear level. IGA success rates at week eight were 15 percent for the control cream, compared to 43 percent for PAC‐14028 cream at 0.1%, 38 percent for 0.3% and 57 percent 1.0%. The efficacy of PAC‐14028 cream was similar to a commonly used non‐steroidal cream called pimecrolimus but with a far lower incidence of unwanted side‐effects.